Worth reading
29Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Acquisition of the shares in questionDisclosing companyOPTiM CORPORATION
Execution Date / Effective Date2 November 2026 (share acquisition and conversion into a subsidiary completed)
Target company
Medical systems and medical consulting
Location 4-34-16 Shibamata, Katsushika-ku, TokyoDate of incorporation 30 March 2018
| Item | Details |
|---|---|
| Transaction name | Acquisition of the shares in question |
| Name of the Subject Company | MediTech株式会社 |
| Business Description of the Subject Company | Medical systems and medical consulting |
| Location of the Subject Company | 4-34-16 Shibamata, Katsushika-ku, Tokyo |
| Date of Establishment of the Subject Company | 30 March 2018 |
| Execution Date / Effective Date | 2 November 2026 (share acquisition and conversion into a subsidiary completed) |
Items this document does not state (26)
Counterparty nameCapital Stock of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The transaction is expected to generate business synergies, including more advanced diagnostic support, stronger collaboration among medical institutions and a reduced administrative burden for healthcare professionals, by combining MediTech’s medical image-sharing technology and knowledge of clinical settings with OPTiM’s AI, IoT and Robotics technologies. The Company also stated that it aims to enhance corporate value over the medium to long term by expanding its healthcare business and accumulating recurring revenue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.